Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety, tolerability and efficacy of MHV370 in Sjögren's syndrome and mixed connective tissue disease was terminated, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Connective Tissue Disease
• Sjögren Syndrome

Drugs mentioned

• MHV370

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjogren Syndrome, Mixed Connective Tissue Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-07-08